Status of work on January
AOTMiT begins work on the Ministry of Health’s orders in December:
- Remsima (infliximab) in the treatment of patients with ulcerative colitis
- Remsima (infliximab) in the treatment of patients with Crohn’s disease
- Omjjara (momelotinib) in the treatment of patients with myeloproliferative neoplasms
- Reblozyl (luspatercept) for the treatment of adult patients with myelodysplastic syndromes with associated transfusion-dependent anemia
- Briumvi (ublituximab) in the treatment of patients with multiple sclerosis
The listed orders are available on the AOTMiT Public Information Bulletin.